导管消融时代房颤合并心衰患者的节律控制:随机数据分层汇总分析
该分层汇总分析纳入11项随机研究共3598例房颤合并心衰患者,比较抗心律失常药物或导管消融节律控制与室率控制/药物治疗。抗心律失常药物节律控制与室率控制相比全因死亡率相似但再住院率更高;导管消融节律控制较药物治疗显著降低全因死亡率和再住院率,改善左室射血分数和生活质量,减少心律失常复发。
要点
- 导管消融节律控制可显著降低房颤合并心衰患者全因死亡率和再住院率。
- 抗心律失常药物节律控制未降低死亡率,且再住院率显著高于室率控制。
- 导管消融显著改善左室射血分数、降低心律失常复发并提高生活质量。
核心结论
- 导管消融作为节律控制策略可显著改善房颤合并心衰患者的生存率、减少再住院、提高窦性心律维持率、有助于保护心功能并改善生活质量。
研究设计与样本
- 分层汇总分析纳入11项随机研究共3598例房颤合并心衰患者,其中子集A(抗心律失常药物 vs 室率控制)2486例,子集B(导管消融 vs 药物治疗)1112例。
主要发现
- 抗心律失常药物节律控制与室率控制相比,全因死亡率相似(OR 0.96,P=0.65),再住院率显著更高(OR 1.25,P=0.01),卒中和血栓栓塞事件率相似(OR 0.91,P=0.76)。
- 导管消融节律控制与药物治疗相比,全因死亡率显著更低(OR 0.51,P=0.0003),再住院率更低(OR 0.44,P=0.003),卒中事件率相似(OR 0.59,P=0.27)。
- 导管消融较药物治疗显著改善左室射血分数(WMD 6.8%,P=0.0004),心律失常复发率更低(29.6% vs 80.1%,OR 0.04,P<0.00001),明尼苏达心衰生活质量问卷评分改善更显著(WMD -9.1,P=0.007)。
临床怎么用
- 对于房颤合并心衰患者,导管消融节律控制可考虑作为改善预后和生活质量的策略。
- 抗心律失常药物节律控制未显示生存获益且再住院风险增加,选择时需权衡。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: The optimal treatment for patients with atrial fibrillation (AF) and heart failure (HF) has been a subject of debate for years. We aimed to evaluate the efficacy and safety of rhythm control strategy in patients with AF complicated with HF regarding hard clinical endpoints. METHODS AND RESULTS: Up-to-date randomized data comparing rhythm control using antiarrhythmic drugs (AADs) vs. rate control (Subset A) or rhythm control using catheter ablation vs. medical therapy (Subset B) in AF and HF patients were pooled. The primary outcomes were all-cause mortality, re-hospitalization, stroke, and thromboembolic events. A total of 11 studies involving 3598 patients were enrolled (Subset A: 2486; Subset B: 1112). As compared with medical rate control, the AADs rhythm control was associated with similar all-cause mortality [odds ratio (OR): 0.96, P = 0.65], significantly higher rate of re-hospitalization (OR: 1.25, P = 0.01), and similar rate of stroke and thromboembolic events (OR: 0.91, P = 0.76,); however, as compared with medical therapy, catheter ablation rhythm control was associated with significantly lower all-cause mortality (OR: 0.51, P = 0.0003), reduced re-hospitalization rate (OR: 0.44, P = 0.003), similar rate of stroke events (OR: 0.59, P = 0.27), greater improvement in left ventricular ejection fraction [weighted mean difference (WMD): 6.8%, P = 0.0004], lower arrhythmia recurrence (29.6% vs. 80.1%, OR: 0.04, P < 0.00001), and greater improvement in quality of life (Minnesota Living with Heart Failure Questionnaire score) (WMD: -9.1, P = 0.007). CONCLUSION: Catheter ablation as rhythm control strategy substantially improves survival rate, reduces re-hospitalization, increases the maintenance rate of sinus rhythm, contributes to preserve cardiac function, and improves quality of life for AF patients complicated with HF.
引用
- Chen S, Pürerfellner H, Meyer C, et al. Rhythm control for patients with atrial fibrillation complicated with heart failure in the contemporary era of catheter ablation: a stratified pooled analysis of randomized data. Eur Heart J. 2020. PMID: 31298266. doi:10.1093/eurheartj/ehz443
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。